Pembrolizumab-Induced Toxic Epidermal Necrolysis

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab, is a cornerstone in cancer treatment.
• Pembrolizumab targets the programmed cell death-1 (PD-1) pathway to enhance anti-tumor immune responses.
• Metastatic non-small cell lung cancer (NSCLC) is a significant indication for pembrolizumab therapy.

Observation:

• A rare but severe adverse event, toxic epidermal necrolysis (TEN), was observed in a patient receiving pembrolizumab.
• The TEN reaction occurred shortly after the second dose of pembrolizumab, necessitating its discontinuation.
• This case highlights a potentially life-threatening dermatological complication associated with anti-PD-1 therapy.

Findings:

• The case report details a 50-year-old male patient who developed TEN while undergoing treatment for metastatic NSCLC with pembrolizumab.
• Literature review identified four similar cases of TEN associated with pembrolizumab, underscoring its occurrence across different patient profiles.
• The management of TEN remains challenging, with varied responses to treatments like corticosteroids, intravenous immunoglobulin (IVIG), and cyclosporine.

Implications:

• Oncologists must be vigilant for the possibility of TEN as an adverse reaction to pembrolizumab.
• Prompt diagnosis and intervention for TEN are critical for improving patient prognosis and minimizing morbidity.
• Further research into the mechanisms and optimal management strategies for pembrolizumab-induced TEN is warranted.